Mizuho Securities USA Reiterates Buy Rating, $93 PT on Questcor Pharmaceuticals on Stock Price Weakness

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

In a report published Tuesday, Mizuho Securities USA analyst Mario Corso reiterated a Buy rating and $93.00 price target on

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Questcor Pharmaceuticals

(NASDAQ: QCOR).In the report, Mizuho Securities USA noted, “In the wake of today's stock price weakness on short report that FTC will challenge Synacthen deal, we ascertained that QCOR hasn't received a formal FTC inquiry, and anything informal might just be in response to updated HSR guidelines. Even if FTC pursued a court challenge, could take 2+ years to decide, and most recent product case went in favor of acquirer even though products looked more similar than Acthar/Synacthen.”Questcor Pharmaceuticals closed on Monday at $56.26.